{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:42:59Z","timestamp":1780926179670,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":162,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100518","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:37:10Z","timestamp":1749757030000},"page":"100518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1016","volume":"24","author":[{"given":"Qaiser","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glorette","family":"Abueg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ramdial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday R.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheath","family":"Alatrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lrr.2025.100518_bib0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2016.1.16","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"2016","author":"Sullivan","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Prog"},{"issue":"9","key":"10.1016\/j.lrr.2025.100518_bib0002","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41375-023-01968-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies","volume":"37","author":"Cuglievan","year":"2023","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.lrr.2025.100518_bib0003","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.lrr.2025.100518_bib0004","article-title":"Recent advances in the biology and CD123-directed treatment of blastic plasmacytoid dendritic cell neoplasm","author":"Pemmaraju","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.lrr.2025.100518_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050595","article-title":"Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects","volume":"11","author":"Sapienza","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.lrr.2025.100518_bib0006","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.lrr.2025.100518_bib0007","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032904","article-title":"Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: a review","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine"},{"issue":"22","key":"10.1016\/j.lrr.2025.100518_bib0008","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/bloodadvances.2023011308","article-title":"Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis","volume":"7","author":"Murthy","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.lrr.2025.100518_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jha2.856","article-title":"Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent\/young adult patients","volume":"5","author":"Pemmaraju","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.lrr.2025.100518_bib0010","first-page":"1","article-title":"Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations","author":"Pemmaraju","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"10.1016\/j.lrr.2025.100518_bib0011","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"1","key":"10.1016\/j.lrr.2025.100518_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","article-title":"Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"57","author":"Bashir","year":"2022","journal-title":"Bone Marrow. Transplant"},{"issue":"5","key":"10.1016\/j.lrr.2025.100518_bib0013","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.14954","article-title":"Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study","volume":"179","author":"Kharfan-Dabaja","year":"2017","journal-title":"Br. J. Haematol"},{"issue":"4","key":"10.1016\/j.lrr.2025.100518_bib0014","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.21686","article-title":"The challenges of clinical trials in rare diseases","volume":"187","author":"Mellerio","year":"2022","journal-title":"Br. J. Dermatol"},{"key":"10.1016\/j.lrr.2025.100518_bib0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-90-481-9485-8_5","article-title":"The importance of case reports in advancing scientific knowledge of rare diseases","volume":"686","author":"Carey","year":"2010","journal-title":"Adv. Exp. Med. Biol"},{"issue":"3","key":"10.1016\/j.lrr.2025.100518_bib0016","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1097\/HS9.0000000000000841","article-title":"Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel","volume":"7","author":"Pagano","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.lrr.2025.100518_bib0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.36401\/JIPO-23-43","article-title":"Overcoming tagraxofusp-erzs monotherapy resistance in blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world clinical setting","volume":"7","author":"Dhakal","year":"2024","journal-title":"J. Immunother Precis Oncol"},{"key":"10.1016\/j.lrr.2025.100518_bib0018","unstructured":"ClinicalTrials.gov. Study of tagraxofusp for post-transplant maintenance for patients with CD 123+ AML, MF and CMML (HSCT 002). ClinicalTrials.gov Identifier: NCT05233618. Updated March 10, 2023. Accessed March 19, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05233618."},{"issue":"13","key":"10.1016\/j.lrr.2025.100518_bib0019","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/cncr.35315","article-title":"Tagraxofusp, a first-in-class CD123-targeted agent: five-year postapproval comprehensive review of the literature","volume":"130","author":"Jen","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.lrr.2025.100518_bib0020","unstructured":"ClinicalTrials.gov. Tagraxofusp and azacitidine for maintenance treatment in patients with CD123 positive AML and MDS following donor hematopoietic cell transplant. Updated October 29, 2024. Accessed January 13, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06498973."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:46:49Z","timestamp":1764852409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"alternative-id":["S2213048925000202"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100518","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100518"}}